Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production

Takahiro Nakamura, Toshio Kukita, Takeo Shobuike, Kengo Nagata, Hiro Take, Kenji Ogawa, Takao Hotokebuchi, Osamu Kohashi, Akiko Kukita

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Osteoclasts are bone-resorptive multinucleated cells that are differentiated from hemopoietic cell lineages of monocyte/macrophages in the presence of receptor activator of NF-κB ligand (RANKL) and M-CSF. Downstream signaling molecules of the receptor of RANKL, RANK, modulate the differentiation and the activation of osteoclasts. We recently found that histone deacetylase inhibitors (HDIs), known as anticancer agents, selectively suppressed osteoclastogenesis in vitro. However, the molecular mechanism underlying inhibitory action of HDIs in osteoclastogenesis and the effect of HDIs on pathological bone destruction are still not remained to be elucidated. In this study, we show that a depsipeptide, FR901228, inhibited osteoclast differentiation by not only suppressing RANKL-induced nuclear translocation of NFATc1 but also increasing the mRNA level of IFN-β, an inhibitor of osteoclastogenesis. The inhibition of osteoclast formation by FR901228 was abrogated by the addition of IFN-β-neutralizing Ab. In addition, treatment of adjuvant-induced arthritis in rats revealed that FR901228 inhibited not only disease development in a prophylactic model but also bone destruction in a therapeutic model. Furthermore, immunostaining of the joints of therapeutically treated rats revealed significant production of IFN-β in synovial cells. Taken together, these data suggest that a HDI inhibits osteoclastogenesis and bone destruction by a novel action to induce the expression of osteoclast inhibitory protein, IFN-β.

Original languageEnglish
Pages (from-to)5809-5816
Number of pages8
JournalJournal of Immunology
Volume175
Issue number9
Publication statusPublished - Nov 1 2005

Fingerprint

Histone Deacetylases
Osteoclasts
Osteogenesis
Histone Deacetylase Inhibitors
Bone and Bones
Depsipeptides
Macrophage Colony-Stimulating Factor
Experimental Arthritis
Cell Lineage
Antineoplastic Agents
Monocytes
Joints
Macrophages
Ligands
Messenger RNA
romidepsin
Proteins

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production. / Nakamura, Takahiro; Kukita, Toshio; Shobuike, Takeo; Nagata, Kengo; Take, Hiro; Ogawa, Kenji; Hotokebuchi, Takao; Kohashi, Osamu; Kukita, Akiko.

In: Journal of Immunology, Vol. 175, No. 9, 01.11.2005, p. 5809-5816.

Research output: Contribution to journalArticle

Nakamura, T, Kukita, T, Shobuike, T, Nagata, K, Take, H, Ogawa, K, Hotokebuchi, T, Kohashi, O & Kukita, A 2005, 'Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production', Journal of Immunology, vol. 175, no. 9, pp. 5809-5816.
Nakamura, Takahiro ; Kukita, Toshio ; Shobuike, Takeo ; Nagata, Kengo ; Take, Hiro ; Ogawa, Kenji ; Hotokebuchi, Takao ; Kohashi, Osamu ; Kukita, Akiko. / Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production. In: Journal of Immunology. 2005 ; Vol. 175, No. 9. pp. 5809-5816.
@article{47e755b4a2ea47fba9fa059e5db338be,
title = "Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production",
abstract = "Osteoclasts are bone-resorptive multinucleated cells that are differentiated from hemopoietic cell lineages of monocyte/macrophages in the presence of receptor activator of NF-κB ligand (RANKL) and M-CSF. Downstream signaling molecules of the receptor of RANKL, RANK, modulate the differentiation and the activation of osteoclasts. We recently found that histone deacetylase inhibitors (HDIs), known as anticancer agents, selectively suppressed osteoclastogenesis in vitro. However, the molecular mechanism underlying inhibitory action of HDIs in osteoclastogenesis and the effect of HDIs on pathological bone destruction are still not remained to be elucidated. In this study, we show that a depsipeptide, FR901228, inhibited osteoclast differentiation by not only suppressing RANKL-induced nuclear translocation of NFATc1 but also increasing the mRNA level of IFN-β, an inhibitor of osteoclastogenesis. The inhibition of osteoclast formation by FR901228 was abrogated by the addition of IFN-β-neutralizing Ab. In addition, treatment of adjuvant-induced arthritis in rats revealed that FR901228 inhibited not only disease development in a prophylactic model but also bone destruction in a therapeutic model. Furthermore, immunostaining of the joints of therapeutically treated rats revealed significant production of IFN-β in synovial cells. Taken together, these data suggest that a HDI inhibits osteoclastogenesis and bone destruction by a novel action to induce the expression of osteoclast inhibitory protein, IFN-β.",
author = "Takahiro Nakamura and Toshio Kukita and Takeo Shobuike and Kengo Nagata and Hiro Take and Kenji Ogawa and Takao Hotokebuchi and Osamu Kohashi and Akiko Kukita",
year = "2005",
month = "11",
day = "1",
language = "English",
volume = "175",
pages = "5809--5816",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "9",

}

TY - JOUR

T1 - Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production

AU - Nakamura, Takahiro

AU - Kukita, Toshio

AU - Shobuike, Takeo

AU - Nagata, Kengo

AU - Take, Hiro

AU - Ogawa, Kenji

AU - Hotokebuchi, Takao

AU - Kohashi, Osamu

AU - Kukita, Akiko

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Osteoclasts are bone-resorptive multinucleated cells that are differentiated from hemopoietic cell lineages of monocyte/macrophages in the presence of receptor activator of NF-κB ligand (RANKL) and M-CSF. Downstream signaling molecules of the receptor of RANKL, RANK, modulate the differentiation and the activation of osteoclasts. We recently found that histone deacetylase inhibitors (HDIs), known as anticancer agents, selectively suppressed osteoclastogenesis in vitro. However, the molecular mechanism underlying inhibitory action of HDIs in osteoclastogenesis and the effect of HDIs on pathological bone destruction are still not remained to be elucidated. In this study, we show that a depsipeptide, FR901228, inhibited osteoclast differentiation by not only suppressing RANKL-induced nuclear translocation of NFATc1 but also increasing the mRNA level of IFN-β, an inhibitor of osteoclastogenesis. The inhibition of osteoclast formation by FR901228 was abrogated by the addition of IFN-β-neutralizing Ab. In addition, treatment of adjuvant-induced arthritis in rats revealed that FR901228 inhibited not only disease development in a prophylactic model but also bone destruction in a therapeutic model. Furthermore, immunostaining of the joints of therapeutically treated rats revealed significant production of IFN-β in synovial cells. Taken together, these data suggest that a HDI inhibits osteoclastogenesis and bone destruction by a novel action to induce the expression of osteoclast inhibitory protein, IFN-β.

AB - Osteoclasts are bone-resorptive multinucleated cells that are differentiated from hemopoietic cell lineages of monocyte/macrophages in the presence of receptor activator of NF-κB ligand (RANKL) and M-CSF. Downstream signaling molecules of the receptor of RANKL, RANK, modulate the differentiation and the activation of osteoclasts. We recently found that histone deacetylase inhibitors (HDIs), known as anticancer agents, selectively suppressed osteoclastogenesis in vitro. However, the molecular mechanism underlying inhibitory action of HDIs in osteoclastogenesis and the effect of HDIs on pathological bone destruction are still not remained to be elucidated. In this study, we show that a depsipeptide, FR901228, inhibited osteoclast differentiation by not only suppressing RANKL-induced nuclear translocation of NFATc1 but also increasing the mRNA level of IFN-β, an inhibitor of osteoclastogenesis. The inhibition of osteoclast formation by FR901228 was abrogated by the addition of IFN-β-neutralizing Ab. In addition, treatment of adjuvant-induced arthritis in rats revealed that FR901228 inhibited not only disease development in a prophylactic model but also bone destruction in a therapeutic model. Furthermore, immunostaining of the joints of therapeutically treated rats revealed significant production of IFN-β in synovial cells. Taken together, these data suggest that a HDI inhibits osteoclastogenesis and bone destruction by a novel action to induce the expression of osteoclast inhibitory protein, IFN-β.

UR - http://www.scopus.com/inward/record.url?scp=27144487343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144487343&partnerID=8YFLogxK

M3 - Article

C2 - 16237073

AN - SCOPUS:27144487343

VL - 175

SP - 5809

EP - 5816

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 9

ER -